Seattle Genetics is a biotechnology company headquartered in Bothell, Washington. It was incorporated on July 17, 1997 and is listed on the NASDAQ Stock Market. Its main area of business is developing antibody-based therapies for cancer treatments. The treatments involve injecting special antibodies into the body of a cancer patient in order to kill cancer cells.
Currently, the company’s flagship product is Adcetris. This drug is already being sold in at least 50 countries around the world including Canada, the US, Japan and EU member countries. The drug, technically referred to as Brentuximab Vedotin, is the first in a new class of antibody-drug conjugates.
After its incorporation, Seattle Genetics grew fast due to its innovative products. Currently, the company has over 650 employees. Most of these employees are experts in research and development of drugs. Over the years, Seattle Genetics has been involved in different collaborations such as the 2009 collaboration with GlaxoSmithKline, the 2010 collaboration with Genentech, and the 2011 collaboration with Oxford BioTherapeutics. Apart from Adcetris, the company has manufactured other products such as SGN-75, SGN-CD19A, ASG-5ME and ASG-22ME.
The current chief executive officer of the firm is Clay Siegall. He is the founder of the company. He is also the President of the firm and a member of its Board of Directors. In his determination to see the company succeed, Siegall has been involved in different capital raising initiatives such as the 2001 initial public offering. In total, he has been able to raise more than $1.2 billion in capital.
Siegall is an alumnus of the University of Maryland. Here, he graduated with a Bachelor of Science Zoology degree. He received his doctorate in Genetics from The George Washington University. Clay began his professional career at National Cancer Institute in 1988 before joining Bristol-Myers Squibb Pharmaceutical in 1991. He resigned in 1997 to found Seattle Genetics.
Apart from managing Seattle Genetics, Siegall also sits on the boards of several companies. These corporations include Alder Biopharmaceutical, Mirna Therapeutics and Ultragenyx Pharmaceutical. He is also an inventor and an author. Currently, he has 15 patents to his name and at least 70 publications. Most of Siegall’s publications focus on cancer and genetics.
Read More here: